Show simple item record

dc.contributor.authorZhou, Jiecan
dc.contributor.authorHe, Fazhong
dc.contributor.authorSun, Bao
dc.contributor.authorLiu, Rong
dc.contributor.authorGao, Yongchao
dc.contributor.authorRen, Huan
dc.contributor.authorShu, Yan
dc.contributor.authorChen, Xiaoping
dc.contributor.authorLiu, Zhaoqian
dc.contributor.authorZhou, Honghao
dc.contributor.authorDeng, Sheng
dc.contributor.authorXu, Heng
dc.contributor.authorLi, Jianmin
dc.contributor.authorXu, Linyong
dc.contributor.authorZhang, Wei
dc.date.accessioned2021-03-29T14:00:50Z
dc.date.available2021-03-29T14:00:50Z
dc.date.issued2019-03-27
dc.identifier.urihttp://hdl.handle.net/10713/15043
dc.description.abstractTribbles homolog 3 (TRIB3) mediating signaling pathways are closely related to blood pressure regulation. Our previous findings suggested a greater benefit on vascular outcomes in patients carrying TRIB3 (251, A > G, rs2295490) G allele with good glucose and blood pressure control. And TRIB3 (rs2295490) AG/GG genotypes were found to reduce primary vascular events in type 2 diabetic patients who received intensive glucose treatment as compared to those receiving standard glucose treatment. However, the effect of TRIB3 genetic variation on antihypertensives was not clear in essential hypertension patients. A total of 368 patients treated with conventional dosage of antihypertensives (6 groups, grouped by atenolol/bisoprolol, celiprolol, doxazosin, azelnidipine/nitrendipine, imidapril, and candesartan/irbesartan) were enrolled in our study. Genetic variations were successfully identified by sanger sequencing. A linear mixed model analysis was performed to evaluate blood pressures among TRIB3 (251, A > G) genotypes and adjusted for baseline age, gender, body mass index, systolic blood pressure (SBP), diastolic blood pressure (DBP), total cholesterol and other biochemical factors appropriately. Our data suggested that TRIB3 (251, A > G) AA genotype carriers showed better antihypertensive effect than the AG/GG genotype carriers [P = 0.014 for DBP and P = 0.042 for mean arterial pressure (MAP)], with a maximal reduction of DBP by 4.2 mmHg and MAP by 3.56 mmHg after azelnidipine or nitrendipine treatment at the 4th week. Similar tendency of DBP-change and MAP-change was found for imidapril (ACEI) treatment, in which marginally significances were achieved (P = 0.073 and 0.075, respectively). Against that, we found that TRIB3 (251, A > G) AG/GG genotype carriers benefited from antihypertensive therapy of ARBs with a larger DBP-change during the period of observation (P = 0.036). Additionally, stratified analysis revealed an obvious difference of the maximal blood pressure change (13 mmHg for the MAP between male and female patients with AA genotype who took ARBs). Although no significant difference in antihypertensive effect between TRIB3 (251, A > G) genotypes in patients treated with α, β-ADRs was observed, we found significant difference in age-, sex-dependent manner related to α, β-ADRs. In conclusion, our data supported that TRIB3 (251, A > G) genetic polymorphism may serve as a useful biomarker in the treatment of hypertension.en_US
dc.description.urihttps://doi.org/10.3389/fphar.2019.00236en_US
dc.language.isoenen_US
dc.publisherFrontiers Media S.A.en_US
dc.relation.ispartofFrontiers in Pharmacologyen_US
dc.subjectTRIB3en_US
dc.subjectantihypertensive agentsen_US
dc.subjectessential hypertensionen_US
dc.subjectpolymorphismen_US
dc.subjectrs2295490en_US
dc.titlePolytropic Influence of rs2295490 Genetic Polymorphism on Response to Antihypertensive Agents in Patients With Essential Hypertension.en_US
dc.typeArticleen_US
dc.identifier.doi10.3389/fphar.2019.00236
dc.identifier.pmid30971918
dc.source.journaltitleFrontiers in pharmacology
dc.source.volume10
dc.source.beginpage236
dc.source.endpage
dc.source.countrySwitzerland


This item appears in the following Collection(s)

Show simple item record